Cerecin, a global biotech firm focused on neurometabolism, has become an industry partner in the NIHR HealthTech Research Centre in Brain Health, joining established players such as GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations.
The research centre, hosted at King’s College London and the South London and Maudsley NHS Foundation Trust, aims to improve dementia diagnosis, care, and treatment. It employs brain scanning, blood sampling, computerized tests, and digital tools to develop earlier and more effective diagnostic methods, with a goal to reduce the societal burden of dementia.
Cerecin claims that joining this collaboration will enhance innovation through academic-industry synergy and support advancement across its drug development pipeline. The company is currently advancing its lead candidate, tricaprilin, in the Phase 3 ALTER AD trial targeting mild to moderate Alzheimer’s disease dementia.
Cerecin said that its proprietary approach delivers medium-chain fatty acids to the liver mitochondria, increasing ketone production to fuel metabolically compromised brain cells and bypass impaired glucose metabolism.
